Head-to-head · WeighScore
Rebody Health vs Zealthy
The verdict
Rebody Health takes it — 67.7/100 to 46.7/100.
Rebody Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rebody Health (rebodyhealth.com), operated by Compound Technologies Inc., is a transparent-pricing GLP-1 and wellness telehealth service that publishes prices up front.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Rebody Health | Zealthy |
|---|---|---|
| WeighScore | 67.7/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #162 | #496 |
| Semaglutide | $200/mo (starting dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $250/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 47 states | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #162 · C
Strengths
- Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
- Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
- Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
- Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
- Names its operating company (Compound Technologies Inc.) and references LegitScript approval
Where it loses points
- Individual compounding pharmacies are not named on the marketing site
- Not available in Massachusetts, Rhode Island, or Vermont
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.